Search results
Results from the WOW.Com Content Network
Dec. 30—HARRISBURG — Snyder, Union and Montour counties are among 50 counties in Pennsylvania that have agreed to join a historic opioid settlement that would bring more than $1 billion to ...
Nov. 1—WILKES-BARRE — The Department of Drug and Alcohol Programs (DDAP) this week announced the availability of $2 million in funding to implement community-based prevention services ...
Dec. 30—More than 75% of Pennsylvania's counties have already signed on to settle a case against a few of the opioid industries' biggest players that would spread $1 billion across the state in ...
The Pennsylvania department of drug and alcohol programs formed in July 2012 due to the change in government proposed in Pennsylvania Act 50 in 2010. This department was originally under the department of health but changed to its own organization to focus solely on drug and alcohol-related addictions and problems.
In Pennsylvania, there’s currently no single resource for people to see how counties and local governments plan to spend the money. But understanding the process can help you influence it.
The university also began an "Opioid Stewardship Committee" to "…consistently and frequently address opioid stewardship." [3] Opioid data for Alabama indicated that, from 2006 to 2014 2.3 billion pain pills were prescribed in the state. McKesson Corporation distributed 728 million of these pain pills; Par Pharmaceutical manufactured 713 million.
With McKeesport signing on in November, Allegheny County will get a full payout from the opioid settlement fund this year. Opioid settlement: Allegheny County won’t receive $479K penalty after ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...